PHAT

Phathom Pharmaceuticals Inc

Feb 26 • 04:00PM ET

13.56

+1.24 10.06 %

Healthcare • Biotechnology • USA • NASD

Feb 26, 6:43 PMPhathom tops Q4 2025 estimates, hits top-end 2025 guidance, targets 2026 operating profitability with strengthened balance sheet

Peers: NBIX BPMC AXSM BTAI ACAD VKTX MDGL PTGX RDUS XENE

| Held by: VTI IWM VXF XPH IBB SURI IWN SCHA VTWO DWAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.81	Insider Own	39.34%	Shs Outstand	71.04M	Perf Week	13.19%
Market Cap	1.06B	Forward P/E	8.77	EPS next Y	1.55	Insider Trans	-0.00%	Shs Float	47.49M	Perf Month	-4.71%
Enterprise Value	1.51B	PEG	-	EPS next Q	-0.27	Inst Own	45.25%	Short Float	24.00%	Perf Quarter	-8.50%
Income	-274.55M	P/S	7.21	EPS this Y	105.01%	Inst Trans	-5.92%	Short Ratio	10.71	Perf Half Y	7.79%
Sales	147.19M	P/B	-	EPS next Y	918.31%	ROA	-87.53%	Short Interest	11.40M	Perf YTD	-18.26%
Book/sh	-5.95	P/C	7.85	EPS next 5Y	-	ROE	-	52W High	18.31 -25.94%	Perf Year	134.20%
Cash/sh	1.73	P/FCF	-	EPS past 3/5Y	-10.82% 12.50%	ROIC	-202.37%	52W Low	2.21 513.57%	Perf 3Y	42.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	87.25%	Volatility	8.04% 6.81%	Perf 5Y	-69.22%
Dividend TTM	-	EV/Sales	10.26	EPS Y/Y TTM	33.03%	Oper. Margin	-145.03%	ATR (14)	0.94	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.19	Sales Y/Y TTM	460.30%	Profit Margin	-186.53%	RSI (14)	54.76	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	2.23	EPS Q/Q	69.16%	SMA20	7.70%	Beta	0.51	Target Price	22.67
Payout	-	Debt/Eq	-	Sales Q/Q	202.74%	SMA50	-5.89%	Rel Volume	1.69	Prev Close	12.32
Employees	427	LT Debt/Eq	-	Earnings	Feb 26 BMO	SMA200	16.63%	Avg Volume	1.06M	Price	13.56
IPO	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	29.61% 0.72%	Trades		Volume	1,798,656	Change	10.06%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Raymond James	Strong Buy	$28
Dec-09-25	Initiated	Barclays	Equal Weight	$16
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight	$23
May-03-24	Initiated	Stifel	Buy	$24
Jan-05-24	Reiterated	Needham	Buy	$23 → $26
Aug-09-23	Initiated	H.C. Wainwright	Buy	$28
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy	$21
Oct-21-22	Initiated	Jefferies	Buy	$16
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral	$40 → $48
Feb-17-21	Initiated	BMO Capital Markets	Outperform	$63
Feb-02-21	Initiated	Guggenheim	Buy	$60
Jun-26-20	Downgrade	Goldman	Neutral → Sell	$34
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Needham	Buy	$40
Nov-19-19	Initiated	Jefferies	Buy	$32
Nov-19-19	Initiated	Goldman	Neutral	$32

Show Previous Ratings

Feb-26-26 04:12PM	Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +10.06%
12:15PM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire)
Feb-25-26 07:33AM	What To Expect From Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings (GuruFocus.com) +6.12%
Feb-24-26 09:40AM	Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Loading…
Feb-23-26 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-17-26 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 (GlobeNewswire) +6.16%
Feb-14-26 05:05PM	Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit (MarketBeat)
Feb-05-26 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 (GlobeNewswire) -6.20%
Jan-08-26 08:49AM	Phathom's Early Numbers Show Sales Strength, Eyes 2026 Profitability (Benzinga) -13.72%
05:17AM	Stock Market Today: S&P 500, Dow Jones Futures Decline - AZZ, Northrop Grumman, Immuneering In Focus (Benzinga)
Jan-07-26 10:33PM	Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +10.45%
04:05PM	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Dec-25-25 07:00PM	Raymond James Sees an Attractive Setup in These 2 Strong Buy Stocks (TipRanks)
08:00AM	Loading…
Nov-04-25 08:00AM	Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
Nov-03-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-25 04:24PM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-29-25 09:49AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-25-25 09:59AM	Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease (GlobeNewswire)
Oct-23-25 08:00AM	Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-20-25 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 (GlobeNewswire) +8.10%
Oct-06-25 08:00AM	Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer (GlobeNewswire)
Sep-18-25 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why (Zacks) +6.82%
Sep-08-25 05:04PM	Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High? (Zacks)
Aug-25-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 09:55AM	Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet (Zacks) +8.77%
Aug-20-25 08:00AM	Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing (GlobeNewswire)
08:10AM	Loading…
Aug-07-25 08:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.29%
06:59AM	Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:25AM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
Aug-04-25 08:15AM	Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-28-25 08:00AM	Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 (GlobeNewswire) -8.62%
Jun-23-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.12%
07:59AM	Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Jun-16-25 08:00AM	Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets Through May 3, 2032 (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade (Zacks)
Jun-06-25 12:45PM	Phathom Pharmaceuticals shares soar on FDA exclusivity grant (Investing.com) +90.19%
12:27PM	Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 (GlobeNewswire)
May-15-25 07:59AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.08%
May-08-25 09:35AM	After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) (Zacks)
May-02-25 03:02AM	Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com) -17.86%
May-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.68%
12:09PM	Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:59AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2025 Annual Meeting (GlobeNewswire)
Apr-23-25 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 (GlobeNewswire)
Apr-16-25 08:00AM	Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors (GlobeNewswire) -11.43%
Apr-08-25 07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks) -12.73%
Apr-03-25 11:25AM	Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (Seeking Alpha) -8.83%
08:00AM	Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 04:15PM	Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -18.34% +7.23%
08:00AM	Phathom Pharmaceuticals Announces Leadership Succession (GlobeNewswire)
Mar-31-25 07:59AM	Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA (vonoprazan) (GlobeNewswire) -5.00%
Mar-07-25 02:08AM	Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... (GuruFocus.com) -14.24%
Mar-06-25 09:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 07:21AM	Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result (GuruFocus.com) +8.96%
Feb-24-25 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 (GlobeNewswire) -5.82%
Jan-29-25 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Dec-12-24 09:39AM	Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? (Insider Monkey)
Dec-11-24 08:00AM	Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA (vonoprazan) Tablets (GlobeNewswire) -5.99%
Dec-06-24 09:35AM	Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround (Zacks) +5.88%
Nov-19-24 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know (Zacks) +5.40%
Nov-08-24 06:02AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -8.86%
Nov-07-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:21AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-04-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 (GlobeNewswire) +8.29%
Oct-27-24 12:00PM	Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting (GlobeNewswire)
Aug-29-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-24 08:00AM	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Aug-08-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
08:00AM	Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients (GlobeNewswire)
Jul-29-24 07:59AM	Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults (GlobeNewswire) -7.68%
Jun-09-24 07:00AM	Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now (InvestorPlace)
Jun-07-24 06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace) +9.50%
May-28-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-24 08:00AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2024 Annual Meeting (GlobeNewswire)
May-13-24 11:02AM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 08:00AM	The 3 Best Healthcare Stocks to Buy in May 2024 (InvestorPlace) -5.60%
May-09-24 09:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 08:02AM	Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target (MT Newswires)
Apr-29-24 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-22-24 03:30AM	SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT (PR Newswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com) -5.38%
11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 08:00AM	Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 08:00AM	Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, VOQUEZNA Can Kick Some Acid (GlobeNewswire)
Mar-08-24 03:05PM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:57AM	Q4 2023 Phathom Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 01:51PM	PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -6.58%

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parikh Asit	Director	Jan 13 '26	Option Exercise	10.30	8,750	90,125	131,000	Jan 15 04:45 PM
Parikh Asit	Director	Dec 19 '25	Option Exercise	10.30	8,750	90,125	122,250	Dec 23 05:00 PM
Basta Steven L	President and CEO	Nov 28 '25	Option Exercise	0.00	90,000	0	131,625	Dec 02 06:45 PM
Breedlove Robert Charles	Principal Accounting Officer	Nov 03 '25	Sale	13.51	524	7,079	47,407	Nov 05 04:30 PM
Basta Steven L	President and CEO	Sep 25 '25	Option Exercise	0.00	90,000	0	90,000	Sep 26 07:03 PM
Breedlove Robert Charles	Principal Accounting Officer	Sep 05 '25	Sale	12.09	461	5,573	47,931	Sep 09 04:40 PM
Breedlove Robert Charles	Principal Accounting Officer	Jul 16 '25	Sale	8.36	1,692	14,152	48,392	Jul 18 04:05 PM
Topper James N	Director	May 21 '25	Buy	3.86	3,780	14,609	59,403	May 23 04:06 PM
Topper James N	Director	May 14 '25	Buy	3.32	6,300	20,919	55,623	May 15 04:17 PM
Topper James N	Director	May 13 '25	Buy	3.16	1,120	3,543	49,323	May 15 04:17 PM
Topper James N	Director	May 09 '25	Buy	3.22	35,602	114,616	35,602	May 13 04:13 PM
Topper James N	Director	May 12 '25	Buy	3.04	12,601	38,301	48,203	May 13 04:13 PM
Parikh Asit	Director	May 06 '25	Buy	2.60	5,000	13,000	90,500	May 08 05:27 PM
Parikh Asit	Director	May 07 '25	Buy	2.40	5,000	11,984	95,500	May 08 05:27 PM
Henderson Molly	CFO and CBO	Apr 07 '25	Sale	4.55	3,678	16,740	89,868	Apr 08 05:01 PM
Parikh Asit	Director	Mar 13 '25	Buy	4.42	10,000	44,200	85,500	Mar 17 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHAT

Phathom Pharmaceuticals Inc

Upgrade your FINVIZ experience